Novel Insight of N6-Methyladenosine in Cardiovascular System

Area of Science:

• Molecular Biology
• Epigenetics
• Cardiovascular Science

Background:

• N6-methyladenosine (m6A) is the most prevalent internal RNA modification in eukaryotes.
• m6A is regulated by "writers" (e.g., METTL3/14), "erasers" (e.g., FTO), and "readers" (e.g., YTHDF proteins).
• Cardiovascular diseases (CVDs) are a major global health concern.

Purpose of the Study:

• To review the role of m6A RNA methylation in cardiovascular physiology and pathology.
• To explore the biological functions, mechanisms, and regulatory factors of m6A in CVDs.
• To highlight m6A as a potential therapeutic target for cardiovascular diseases.

Main Methods:

• Literature review of recent advancements in m6A RNA methylation research.
• Analysis of m6A's impact on various cardiovascular conditions.
• Discussion of downstream target genes and regulatory networks.

Main Results:

• m6A modification is implicated in the initiation and progression of CVDs.
• Specific m6A regulators and readers play critical roles in cardiovascular processes.
• m6A influences atherosclerosis, ischemic diseases, metabolic disorders, and heart failure.

Conclusions:

• m6A RNA methylation is a key player in cardiovascular health and disease.
• Understanding m6A mechanisms provides insights into CVD pathogenesis.
• The m6A pathway presents a promising therapeutic avenue for treating cardiovascular diseases.